www.fdanews.com/articles/87381-agi-happy-with-ibs-treatment-trial
AGI HAPPY WITH IBS TREATMENT TRIAL
June 7, 2006
Pharmaceutical company AGI Therapeutics has announced preliminary results from second phase trials of two of its treatments. The company said results for arverapamil, which is aimed at patients suffering from irritable bowel syndrome (IBS), were positive.